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Abstract. Apoptosis and oxidative stress are essential
for the pathogenesis of acute liver failure and fulminant
hepatic failure. Human placental hydrolysate (hPH) has
been reported to possess antioxidant and anti‑inflammatory
properties. In the present study, the protective effects of hPH
against D‑galactosamine (D‑GalN)‑ and lipopolysaccharide (LPS)‑induced hepatocyte apoptosis were investigated
in vivo. In addition, the molecular mechanisms underlying the
anti‑apoptotic activities of hPH against D‑GalN‑induced cell
death in vitro were examined. Male Sprague‑Dawley rats were
injected with D‑GaIN/LPS with or without the administration
of hPH. Rats were sacrificed 24 h after D‑GaIN/LPS intraperitoneal injection, and the blood and liver samples were collected
for future inflammation and hepatotoxicity analyses. Changes
in cell viability, apoptosis protein expression, mitochondrial
mass, mitochondrial membrane potential, reactive oxygen
species generation, and the levels of proteins and mRNA
associated with a protective mechanism were determined in
HepG2 cells pretreated with hPH for 2 h prior to D‑GalN
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exposure. The findings suggested that hPH treatment effectively
protected against D‑GalN/LPS‑induced hepatocyte apoptosis
by reducing the levels of alanine aminotransferase, aspartate
aminotransferase, lactate dehydrogenase, interleukin‑6, and
tumor necrosis factor‑α, and increasing the level of proliferating cell nuclear antigen. It was also found that hPH inhibited
the apoptotic cell death induced by D‑GalN. hPH activated
the expression of antioxidant enzymes, including superoxide
dismutase, glutathione peroxidase, and catalase, which were
further upregulated by the Kelch‑like ECH2‑associated
protein 1‑p62‑nuclear factor‑erythroid 2‑related factor 2
pathway, a component of oxidative stress defense mechanisms.
Furthermore, hPH markedly reduced cytosolic and mitochondrial reactive oxygen species and rescued mitochondrial loss
and dysfunction through the reduction of damage‑regulated
autophagy modulator, p53, and C/EBP homologous protein.
Collectively, hPH exhibited a protective role in hepatocyte
apoptosis by inhibiting oxidative stress and maintaining cell
homeostasis. The underlying mechanisms may be associated
with the inhibition of endoplasmic reticulum stress and minimization of the autophagy progress.
Introduction
Acute liver failure (ALF), sometimes referred to as fulminant
hepatic failure, is a severe liver disease characterized by
coagulopathy and liver inflammation in patients with previously normal liver function (1). The onset of liver injury, often
accompanied by endotoxemia and hepatocyte death, can result
in high mortality rates in animals and humans, due to the lack
of an effective therapy for ALF, other than liver transplantation (2).
The administration of D‑galactosamine (D‑GalN) and
lipopolysaccharides (LPS) establishes an animal model for
ALF; it severely impairs liver function in laboratory animals,
and can be used to investigate ALF (3). LPS, a type of endotoxin, can cause liver tissue damage through activation of
inflammatory cytokines, including interleukin (IL)‑1β, IL‑6,
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tumor necrosis factor (TNF)‑α, and interferon‑γ (4). A report
suggests that LPS as an inflammatory mediator can stimulate
the production of reactive oxygen species (ROS) and can
be used broadly to induce research models of ALF (5). A
D‑GalN/LPS‑induced animal model of ALF is representative
of human liver failure and has been widely used to investigate
mechanisms and potential therapeutic drugs for clinical use in
treating ALF (2). Increasing evidence has shown that oxidative
stress and hepatocyte apoptosis are two important pathogenic
factors that contribute to D‑GalN/LPS‑induced ALF (6,7).
T h e eva lu a t io n of m e c h a n i sm s i nvolve d i n
D‑GalN/LPS‑induced hepatic apoptosis has indicated that
mitochondria are critical targets for drug toxicity through the
formation of reactive metabolites (8,9). In response to oxidative stress, the cellular machinery of the antioxidative response
is mediated by cytoprotective enzymes in the liver. When it to
comes to oxidation, nuclear factor‑E2‑related factor 2 (Nrf2),
a key sensor in antioxidative stress systems, regulates cellular
defense against oxidative damage (10), contributing to diverse
cellular functions, including proliferation, inﬂammation and
lipid synthesis (11). The aberrant expression or function of Nrf2
has been linked to pathologies, including hepatic steatosis (12)
and diabetic nephropathy (13). Although Nrf2 is regularly
sequestered by Kelch‑like ECH2‑associated protein 1 (Keap1)
in the cytoplasm (14), when activated, it translocates into
the nucleus and upregulates antioxidant response element
(ARE) genes, including superoxide dismutase (SOD)1/SOD2,
catalase, glutamate‑cysteine ligase catalytic subunit (GCLC),
glutamate‑cysteine ligase regulatory subunit (GCLM), heme
oxygenase‑1 (HO‑1), cytochrome P450s, multidrug‑resistant proteins and NAD(P)H dehydrogenase quinone 1
(NQO1) (15,16).
In general, the autophagy‑dependent degradation of
impaired organelles, including the selective degradation of
the endoplasmic reticulum (ER; reticulophagy), mitochondria (mitophagy), and lipid droplets (lipophagy), is a crucial
cellular pathway for maintaining cell homeostasis (17,18).
However, autophagy is also regarded as a pro‑apoptotic factor
and causes ‘type II’ programmed cell death (19). The cellular
damage mediated by p53 has a pathological role in the progression of hepatosteatosis. It is noteworthy that p53 can promote
the expression of damage‑regulated autophagy modulator
(DRAM), an inducer of autophagy‑mediated apoptosis (20).
Previous studies have revealed that human placental
hydrolysate (hPH) is a rich source of various bioactive
substances, including polydeoxyribonucleotides, RNA, DNA,
peptides, amino acids, enzymes, and trace elements, among
others (21). Human placenta has been demonstrated to possess
various therapeutic properties ranging from wound healing
to immunomodulation (22). The use of aqueous extract of
human placenta in wound healing, ophthalmology, infertility,
apoplexy, and epilepsy has evolved from folk knowledge to
modern scientific practice (23). In a previous clinical trial, it
was identified that treatment of hPH ameliorated alcoholic or
nonalcoholic steatohepatitis in patients (24,25). In addition,
hPH has been shown to have a protective effect in ALF via
an anti‑inflammatory response (26). However, the mechanism
underlying this anti‑apoptotic action and the defense mechanism remain to be fully elucidated. Given the various uses
of human placenta for intervention in different diseases, the

present study was undertaken to investigate the protective
effects of hPH against apoptotic hepatocyte cell death in vivo
and in vitro.
Materials and methods
Reagents and antibodies. All chemicals and solvents used
were of the highest analytical grade available. Cell culture
supplies and media, including fetal bovine serum (FBS), phosphate‑buffered saline (PBS), and penicillin‑streptomycin were
purchased from Thermo Fisher Scientific, Inc. (Waltham, MA,
USA). The Cell Counting Kit‑8 (CCK‑8; cat. no. CK04‑11)
was from Dojindo Molecular Laboratories, Inc. (Kumamoto,
Japan). Protease inhibitor cocktail (cat. no. P8340) and
D‑GalN (cat. no. G0500) were purchased from Sigma‑Aldrich;
EMD Millipore (Billerica, MA, USA). Anti‑proliferating
cell nuclear antigen (PCNA; cat. no. ab15497), anti‑Tomm20
(cat. no. ab56783) and anti‑Lamin B1 (cat. no. ab16048)
antibodies were purchased from Abcam (Cambridge, UK).
Anti‑poly (ADP) ribose polymerase (PARP; cat. no. 9532S)
antibody was purchased from Cell Signaling Technology,
Inc. (Beverly, MA, USA). Anti‑B‑cell lymphoma 2 (BCL2;
cat. no. SC‑7382), anti‑Bcl‑2‑associated X protein (BAX;
cat. no. SC‑526), anti‑DRAM (cat. no. SC‑81713), anti‑SOD1
(cat. no. SC‑17767), anti‑SOD2 (cat. no. SC‑130345), anti‑glutathione peroxidase (GPx; cat. no. SC‑133160), anti‑Catalase
(cat. no. SC‑271358), anti‑Keap1 (cat. no. SC‑365626), anti‑HO‑1
(cat. no. SC‑136960), anti‑p53 (cat. no. SC‑126), anti‑GAPDH
(cat. no. SC‑20357), and anti‑Nrf2 (cat. no. SC‑81342) antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Anti‑microtubule‑associated protein
1A/1B‑light chain 3 (LC3)I/II (cat. no. PM036), anti‑phosphorlyated‑p62 (cat. no. PM074), and anti‑p62 (cat. no. PM045)
antibodies were purchased from MBL International
Corporation (Woburn, MA, USA). hPH (Laennec inj.) was
manufactured by Green Cross WellBeing Corporation
(Seongnam, Korea) through the hydrolysis of human placenta
with HCl and pepsin.
Animals and experimental design. Sprague‑Dawley rats (SD)
rats (male, 6‑8 weeks old, weighing ~200‑250 g each) were
purchased from Raonbio, Inc. (Yongin, Korea). These rats
were provided with adequate food and water ad libitum and
were housed in clean cages for 1 week. The laboratory temperature was 24±1˚C and relative humidity was 40‑80%. All
animal experiments were performed according to the Guide
for the Care and Use of Laboratory Animals as published by
the US National Institutes of Health. The present study was
reviewed and approved by the Animal Welfare and Research
Ethics Committee at Chung‑Ang University (Seoul, Korea;
2017‑00003). Acute liver injury was induced by intraperitoneal
injection of LPS (15 µg/kg) together with D‑GalN (700 mg/kg)
dissolved in normal saline, which can increase the sensitivity
of hepatocytes. Blood was collected from the inferior vena cava
24 h following injection of D‑GalN/LPS. The SD rats were
then dissected, and liver tissues were removed immediately for
histological detection. Normal PBS was used in control rats.
hPH (1.2, 2.4, and 3.6 ml/kg) was injected subcutaneously into
each mouse 24, 48, and 72 h prior to D‑GalN/LPS injection.
As a negative control, only D‑GalN/LPS was injected.
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Evaluation of serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST). The collected blood
samples were stored overnight at 4˚C. The serum was isolated
the subsequent day following centrifugation at 15,928 x g
for 10 min at 4˚C. The ALT and AST were detected using a
Hitachi 7600 Series automatic biochemical analyzer (Hitachi,
Ltd., Tokyo, Japan).
Enzyme‑linked immunosorbent assay (ELISA) of cytokines.
Based on a previous study, blood was collected for measuring
TNF‑α (cat. no. 438207) and IL‑6 (cat. no. 437107) at 24 h
post‑D‑GalN/LPS injection. The serum was separated by
centrifugation at 15,928 x g at 4˚C for 10 min. The cytokines
were measured using mouse ELISA kits (BioLegend, Inc.,
San Diego, CA, USA) according to the manufacturer's protocol.
Histopathological evaluation. The liver tissues were immersed
in normal 10% neutral buffered formalin and fixed for 48 h,
dehydrated in a series of graded ethanol, embedded in paraffin
wax, and cut into 5‑µm sections. The paraffin‑embedded
sections were stained with hematoxylin and eosin (H&E) for
pathological analysis under a light microscope. Histological
changes were evaluated using a point‑counting method for the
severity of hepatic injury using an ordinal scale, as previously
described (27). Briefly, the H&E‑stained sections were evaluated at x400 magnification using the point‑counting method
for the severity of hepatic injury with an ordinal scale as
follows: grade 0, minimal or no evidence of injury; grade 1,
mild injury consisting of cytoplasmic vacuolation and focal
nuclear pyknosis; grade 2, moderate to severe injury with
extensive nuclear pyknosis, cytoplasmic hypereosinophilia,
and loss of intercellular borders; and grade 3, severe necrosis
with disintegration of hepatic cords, hemorrhage, and neutrophil infiltration.
Measurement of apoptosis via TUNEL assay. TUNEL was
performed to analyze DNA fragmentation indicative of
cellular apoptosis using the in situ cell death detection kit
(cat. no. ab206386, Abcam), according to the manufacturer's
protocol. The paraffin wax‑embedded tissue sections were
treated with proteinase K, and endogenous peroxidase activity
was blocked with hydrogen peroxide. The sections were
incubated at 37˚C with the terminal TdT nucleotide mixture
for 1 h. The reactions were then terminated, and the slides
were rinsed with PBS. Nuclear labeling was developed with
horseradish peroxidase and diaminobenzidine. The number of
apoptotic cells in each slide from at least five different fields
was analyzed using Image‑Pro Plus software (version 6.0 for
Windows; Media Cybernetics, Inc., Rockville, MD, USA) with
the assistance of a microscope (DM750; Leica Microsystems
GmbH, Wetzlar, Germany). The number of positive cells was
averaged for statistical analysis.
Liver immunohistochemistry. The paraffin sections were
de‑paraffinized and rehydrated. Endogenous peroxidase
was inactivated by incubation in 0.3% hydrogen peroxide in
absolute methanol for 30 min. The sections were incubated
in 5% skim milk for 30 min at room temperature. Antigen
retrieval was performed by microwave (700 W) treatment in
10 mM citrate buffer (pH 6.0) for 15 min. The sections were
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incubated overnight at 4˚C with anti‑PCNA primary antibody
(Abcam) at a dilution of 1:500. Following washing with PBS,
the sections were incubated at room temperature for 30 min
in secondary antibody (Goat Anti‑Rabbit; cat. no. ab205718;
Abcam; 1:1,000). A brown color was developed with 3 diaminobenzidine for 2‑4 min, and the sections were then washed in
distilled water. The number of positively stained brown nuclei
(denoting PCNA) in each slide from at least five different fields
was analyzed using Image‑Pro Plus software (version 6.0
for Windows) with the assistance of a microscope (DM750,
Leica Microsystems GmbH). The number of positive cells was
averaged for statistical analysis.
Cell culture and treatment. Human HepG2 cells, the HepG2
(ATCC HB 8065) cells were purchased from the Korea Cell
Line Bank (Seoul, Korea), and were cultured in Dulbecco's
modified Eagle's medium (DMEM) with 10% (v/v)
heat‑inactivated FBS and 1% penicillin and incubated in a
humidified incubator with 5% CO2, 95% air at 37˚C. A dose
of 5% hPH was used in the time‑course investigation of the
induction of antioxidant enzymes by hPH. To investigate the
protective effects of hPH and its active mechanism on HepG2
cells challenged by D‑GaIN (Sigma; EMD Millipore), the
cells were pretreated with hPH for 2 h, stimulated with 50 mM
D‑GaIN at 37˚C, and harvested for the indicated experiments.
Cell viability assay. The HepG2 cells, treated as described
above, were further treated with 50 mM D‑GalN and incubated for another 24 h, following which the cell viability was
determined using CCK‑8 (Dojindo Molecular Technologies,
Inc.). To determine cell viability, the HepG2 cells were seeded
in 96‑well plates at a density of 1x104 cells/ml and grown for
24 h in a 37˚C incubator. When the cells attained 70‑80%
confluence, they were either left untreated (control group) or
treated with D‑GalN (50 mM), 5% hPH, or 5% hPH + D‑GalN
(50 mM). Following incubation for 24 h, cell morphology
changes were observed under Olympus inverted microscopes
(Olympus Corporation, Tokyo, Japan). The supernatants
were discarded, following which 10% CCK‑8 solution in
fresh DMEM (100 µl) were added to each well. The cells
were then incubated at 37˚C for 1 h, and the absorbance was
measured at 450 nm directly in the wells using a SpectraMax
i3x Multi‑Mode detection platform (Molecular Devices LLC,
Sunnyvale, CA, USA).
Measurement of LDH release. The LDH in the culture
medium was assessed with 0.2 mM NADH and 0.4 mM
pyruvic acid in up to 200 µl PBS at pH 7.4. The LDH concentration in the sample was proportional to the rate of NADH
oxidation measured by absorbance at 334 nm (OD/min) using
the SpectraMax i3x Multi‑Mode detection platform. The LDH
concentration in the culture media was calculated using a
commercial standard LDH assay kit purchased from Abnova
(cat. no. KA0785, Taipei, Taiwan).
DAPI staining. Morphological changes in the apoptotic cells
were assessed by fluorescent microscopy following DAPI
staining. Briefly, the HepG2 cells were seeded at a density of
1x105 cells/ml in 6‑well plates and grown for 24 h in a 37˚C
incubator. Following washing once with PBS, the cells were
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either left untreated (control group) or treated with D‑GalN
(50 mM), 5% hPH, or 5% hPH + D‑GalN (50 mM). Following
incubation for 24 h, the cells were fixed in 4% formaldehyde
for 1 h, and permeabilized with 0.1% Triton X‑100 (Biosesang,
Inc., Seongnam, Korea) for 5 min. Subsequently, DNA‑specific
fluorochrome DAPI (Invitrogen; Thermo Fisher Scientific,
Inc.) was applied to each well, following which samples were
incubated for 10 min in the dark at room temperature. Finally,
the cells were washed three times with PBS and examined
using a confocal microscope (Carl Zeiss AG, Oberkochen,
Germany).
Annexin V‑fluorescein isothiocyanate (FITC)/propidium
iodide (PI) staining and fluorescence images. For apoptotic
cell analysis, the HepG2 (1x104/well) cultures in 96‑well black
plates were exposed to the indicated treatments for 12 h. The
assay was performed according to the manufacturer's protocol
(BD Biosciences, San Jose, CA, USA). Briefly, the cells
were washed twice with PBS and again with binding buffer.
Annexin V‑fluorescein isothiocyanate and PI were added to
each sample, and the mixture was incubated at room temperature for 15 min. The absorbance was read directly in the wells
at 494/518 nm for FITC Annexin V and 535/617 nm for PI
using the SpectraMax i3x Multi‑Mode detection platform.
The populations staining positive for Annexin V and Pl were
compared with the untreated group.
The HepG2 cells were grown to ~70% confluence;
1x105 cells were collected in a Petri dish and either left
untreated (control group) or treated with D‑GalN (50 mM), 5%
hPH, or 5% hPH + D‑GalN (50 mM); and then incubated for
24 h. The cells were then washed with PBS and stained with
10 µg/ml PI for 5 min, and fluorescent images were observed
under a DP70 fluorescence microscope with DP Controller
software (Olympus Corporation; ver. 3.2.276.2).
Measurement of ROS. Cytosolic and mitochondrial ROS
were measured on a 96‑well plate reader as previously
described (28). Briefly, the HepG2 cells were seeded at a
concentration of 1x10 4 cells per well in black 96‑well flat
bottom plates (Thermo Fisher Scientific, Inc.) and allowed to
adhere overnight. Following seeding, the cells were washed
and incubated with serum‑starved medium, D‑GalN (50 nM),
5% hPH, or 5% hPH + D‑GalN (50 mM) for 4 h, followed by
incubation with 2',7'‑dichlorofluorescin diacetate (DCFH‑DA;
10 µM, ex/em: 518/605 nm; Invitrogen; Thermo Fisher
Scientific, Inc.) or MitoSOX™ (5 µM, ex/em: 510/580 nm;
Invitrogen; Thermo Fisher Scientific, Inc.) for 20 min. The
oxidative products were measured with the SpectraMax i3x
Multi‑Mode detection platform.
Measurement of mitochondrial membrane potential (ΔΨm).
The ΔΨm of intact cells was measured as previously
described, (29) with modifications. Briefly, the cells were
washed with PBS and TMRE (200 nM, ex/em: 549/582 nm;
Invitrogen; Thermo Fisher Scientific, Inc.) was added to the
cell suspension. The cells were incubated at 37˚C for 30 min
in the dark. The ΔΨm was measured using the SpectraMax
i3x Multi‑Mode detection platform. The percentage and mean
fluorescence intensity level of the mass were calculated for
each sample.

Determination of mitochondrial mass. Mitochondrial mass
was measured according to fluorescence levels following
staining with MitoTracker Green FM (100 nM, ex/em:
490/525 nm; Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C
for 30 min. Subsequently, the cells were washed once in PBS
and promptly evaluated using the SpectraMax i3x Multi‑Mode
detection platform. The percentage and mean fluorescence
intensity level of the mass were calculated for each sample.
Fluorescence microscopy. The cells (1x106 cells/well) were
prepared on sterilized glass coverslips (BD Biosciences) in
triplicate and then fixed in 4% paraformaldehyde in PBS for
10 min, permeabilized with 0.25% Triton X‑100 in PBS for
10 min and incubated with primary antibodies against Tomm20
(Abcam; 1:500), Nrf2 (Santa Cruz Biotechnology, Inc.; 1:500),
and LC3 (Abcam; 1:500) for 12 h at 4˚C incubator. The cells
were washed to remove excess primary antibodies and incubated with the appropriate fluorescently labeled secondary
antibodies (1:1,000) for 1 h at room temperature. Following
mounting of slides, fluorescence images were acquired using a
confocal microscope (LSM700, Carl Zeiss AG).
Western blot analysis. The cells were lysed in cell lysis buffer
[62.5 mM Tris‑HCl (pH 6.8), 2% sodium dodecyl sulfate
(SDS), 5% β ‑mercaptoethanol, 2 mM phenylmethylsulfonyl
fluoride, protease inhibitors (Complete™; Roche Diagnostics
GmbH, Mannheim, Germany), 1 mM Na3VO4, 50 mM NaF
and 10 mM EDTA]. The protein content of the lysates was
determined using BCA Protein Assay reagent (cat. no. 23225;
Pierce; Thermo Fisher Scientific, Inc.). A 20 µg sample of
protein per lane was separated by 12% SDS‑polyacrylamide
gel electrophoresis and blotted onto polyvinylidene fluoride
membranes (EMD Millipore) which were then saturated with
5% powdered milk in Tris‑buffered saline containing 0.5%
Tween‑20. The blots were then incubated with the appropriate
primary antibodies at a dilution of 1:1,000 or 1:2,000 for 12 h
in a 4˚C incubator, and further incubated with horseradish
peroxidase‑conjugated secondary antibody (1:10,000) for 2 h
at 37˚C. The bound antibodies were detected using enhanced
chemiluminescence (Amersham; GE Healthcare Life
Sciences, Chalfont, UK). Images of the blotted membranes
were captured using the LAS‑1000 lumino‑image analyzer
(Fujifilm, Tokyo, Japan). The protein levels were compared
to those of the appropriate loading control (GAPDH or
non‑phosphorylated proteins).
Reverse transcription‑quantitative polymerase chain reaction
(RT‑qPCR) analysis. Total RNA was extracted from the dorsal
skin using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.).
First‑strand cDNA synthesis from the total RNA template
was performed with PrimeScript RT master mix (Takara
Bio, Inc., Tokyo, Japan). The resulting cDNA was subjected
to real‑time PCR (complementary cDNA, 2 µl; primer, 3 µl;
2X premix SYBR, 5 µl), using qPCR 2X PreMIX SYBR
(Enzynomics, Seoul, Korea) and a CFX‑96 thermocycler
(Bio‑Rad Laboratories, Inc., Hercules, CA, USA). The PCR
conditions used to amplify all genes were as follows: 10 min
at 95˚C and 40 cycles of 95˚C for 10 sec, 60˚C for 15 sec, and
72˚C for 20 sec. The expression data were calculated from
the quantification cycle (Cq) value using the ∆Cq method of
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quantification (30). GAPDH was used for normalization. The
oligonucleotides that were used for qPCR were as follows:
Human ATG8, forward 5'‑CGCACCTTCGAACAAAGA
GT‑3' and reverse, 5'‑GACCATG CTGTGT CCGTT C‑3';
human beclin 1 (BECN1), forward 5'‑AACCTCAGCCGA
AGACTG AA‑3' and reverse, 5'‑CCTCTAGTGCCAGCTCCT
TT‑3'; human cathepsin D (CTSD), forward 5'‑CAAGTTCGA
TGGCATCCTGG‑3' and reverse 5'‑CGGGTGACATTCAGG
TAGGA‑3'; human lysosomal‑associated membrane protein 1
(LAMP1), forward 5'‑CTT TCA AGGTGGA AG GTGzG C‑3'
and reverse 5'‑GATAGTCTGGTAG CCTGCGT‑3'; human
activating transcription factor (ATF)6, forward 5'‑GTGTCA
GAGAACCAGAGGCT‑3' and reverse 5'‑GGTGCCTCCTTT
GATTTGCA‑3'; human ATF4, forward 5'‑ACACTGCTTACG
TTGCCATG‑3' and reverse 5'‑AGACCCACAGAGAACACC
TG‑3'; human C/EBP homologous protein (CHOP), forward
5'‑CATTGCCTTTCTCCTTCGG GG‑3' and reverse 5'‑CCA
GAGAAGCAGGGTCAAGA‑3'.
Statistical analysis. All quantitative data are presented as
the mean ± standard error of the mean for three independent
experiments. Statistical analyses were performed using the
statistical package for SPSS software version 17.0 (IBM
Corp., Armonk, NY, USA). Differences between two groups
were evaluated using a paired Student's t‑test. For multiple
comparisons, one‑way analysis of variance was used followed
by Tukey's multiple comparisons test. P<0.05 was considered
to indicate a statistically significant difference.
Results
Effects of hPH on mortality rates of D‑GalN/LPS‑treated rats.
Acute liver injury leads to high mortality rates in rats. Therefore,
the present study assessed the effects of hPH on D‑GalN
(700 mg/gg)/LPS (15 µg/kg)‑induced mortality. To investigate
whether hPH can protect against liver injury in rats due to
D‑GalN/LPS, the survival rate of D‑GalN/LPS + hPH‑treated
rats was monitored for 24 h (n=12). All saline‑injected rats
survived as the normal control group (n=12). No significant
differences in gross liver examination, body weight, or liver
weight were found between groups (Fig. 1A‑C). As shown
in Fig. 1D, a number of rats died 7 h following D‑GalN/LPS
injection, and the survival rate was 33.3% at 24 h. However,
it was found that hPH pretreatment effectively increased the
survival rate of rats with liver injury induced by D‑GalN/LPS.
Pretreatment with hPH (1.2 ml/kg) increased the survival rate
to 83.3%, and all hPH (2.4 and 3.6 ml/kg)‑treated rats survived.
These results suggested that pretreatment with hPH effectively
protected against D‑GalN/LPS‑induced mortality.
Effects of hPH on serum levels of ALT, AST, and inflamma‑
tory cytokines in LPS/GalN‑induced liver failure in rats. The
serum levels of AST, ALT, LDH, and inflammatory cytokines
are well‑established markers of hepatic injury (31). In order to
investigate the effects of hPH on D‑GalN/LPS‑induced liver
damage, hematological tests were performed. Serum (n=4‑6)
was collected to detect AST, ALT, LDH, IL‑6, and TNF‑α. As
shown in Fig. 1E‑G, LPS/D‑GalN markedly increased serum
levels of AST, ALT, and LDH, whereas hPH reduced these
elevations. As hepatocyte injury resulting from acute liver

2573

injury is accompanied by an elevation in inflammatory cytokines (32), the present study examined the effect of hPH on
hepatotoxicity by measuring serum levels of IL‑6 and TNF‑α
(Fig. 1H and I). The D‑GalN/LPS‑treated rats exhibited significant increases in levels of IL‑6 and TNF‑α compared with
normal rats. In addition, hPH pretreatment significantly inhibited the release of these pro‑inflammatory cytokines compared
with the LPS/D‑GalN group. These results suggested that
hPH effectively protected against LPS/D‑GalN‑induced liver
degeneration and inflammatory responses.
Effects of hPH on hepatotoxicity of hepatocytes. The present
study also investigated histological changes following liver
injury to confirm the protective effects of hPH. The rats
treated with D‑GalN/LPS showed severe histopathological
degeneration evidenced by severe intrahepatic hemorrhaging,
apoptosis, necrosis, ballooned hepatocytes, and hepatocytes
expanded by fat vacuoles, whereas hPH (1.2, 2.4 and 3.6 ml/kg)
treatment ameliorated these changes (Fig. 2A). It has been
suggested that D‑galN/LPS‑induced imbalance between
apoptosis and proliferation in hepatocytes is responsible for
the impairment of liver function. Therefore, hPH‑mediated
modulations of proliferation (PCNA) and apoptosis (TUNEL)
were also evaluated by immunohistochemical analysis
(Fig. 2B and C). A high expression of PCNA and low numbers
of TUNEL‑positive cells were observed in the control group.
However, D‑GalN/LPS markedly reduced PCNA immunoreactivity and significantly increased the number of apoptotic
cells. By contrast, pre‑administration of hPH resulted in an
increase of PCNA‑positive cells and reduced the number of
apoptotic cells in all three dose groups. Graphs showing results
of the staining experiments are shown in Fig. 2D‑F. These
observations indicated that hPH pretreatment ameliorated
hepatic injury by reducing D‑GalN/LPS‑induced hepatocyte
damage in rats.
hPH protects hepatocytes against D‑GalN‑induced apoptosis.
Hepatocyte apoptosis is important in the pathogenesis of liver
disease, including ALF (33). D‑GalN induces hepatocyte
cell death in vivo (34) and in vitro (35); it offers a suitable
experimental model based on its capacity to reduce the intracellular pool of uridine monophosphate in hepatocytes,
inhibiting the synthesis of RNA and proteins, and leading
to cell apoptosis. Therefore, the present study investigated
whether D‑GalN‑induced hepatotoxicity occurred in HepG2
cells. Following D‑GalN stimulation, cell viability decreased
markedly in a dose‑dependent manner. The results revealed a
reduction of 50% at 50 mM D‑GalN and of 82% at 100 mM
D‑GalN in the HepG2 cells (Fig. 3A). The cytotoxic effects
of hPH on HepG2 cells have not been examined previously. The present study used a CCK‑8 assay to evaluate the
dose‑dependent cytotoxic effects of hPH on HepG2 cells. The
results showed that stimulation with hPH had no significant
effect on cell viability at various concentrations (1.25‑5% in
serum‑free DMEM) over 24 h. Therefore, hPH was used at
a concentration of 5% in subsequent experiments (Fig. 3B).
In addition to the D‑GalN‑induced decrease in cell viability
being attenuated by pretreatment with hPH, the concentration
of LDH released from the hepatocytes was also reduced in
the D‑GalN + 5% hPH‑stimulated cells, compared with the
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Figure 1. Protective effects of hPH treatment on D‑GalN/LPS‑induced acute liver failure. hPH (1.2, 2.4, or 3.6 ml/kg) was subcutaneously administered to
rats three times at intervals of 24 h, followed by exposure to 700 mg/kg D‑GalN and 15 µg/kg LPS (D‑GalN/LPS). Livers from each experimental group were
examined 24 h following D‑GalN/LPS challenge. (A) Gross image of livers. Scale bar=1 cm (B) Animal weights (n=4‑6) were measured just prior to sacrifice;
with no statistical difference among groups. (C) Liver weights were measured following sacrifice, with no statistical difference among groups (n=4‑6).
(D) Survival rates of rats were observed for 24 h following D‑GalN/LPS exposure (n=12). Serum (n=4‑6) was collected from animals 24 h following exposure
to D‑GalN/LPS to determine levels of (E) AST, (F) ALT, (G) LDH, (H) IL‑6, and (I) TNF‑α. All data are presented as the mean ± standard error of the mean.
*
P<0.05 and **P<0.01, vs. D‑GalN/LPS group. hPH, human placental hydrolysate; D‑GalN, D‑galactosamine; LPS, lipopolysaccharide; Cont, control; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; IL‑6, interleukin‑6; TNF‑α, tumor necrosis factor‑α.

D‑GalN only‑treated cells (Fig. 3C and D). These results
indicated that hPH protected against D‑GalN‑induced hepatotoxicity in HepG2 cells. Changes in cellular morphology and
cell viability were also evaluated to examine the protective
effects of hPH in D‑GalN‑stimulated HepG2 cells. As shown
in Fig. 3E, the D‑GalN‑stimulated HepG2 cells exhibited a
marked reduction in the number of hepatocytes. However, hPH
pretreatment effectively improved the D‑GalN‑mediated cell
damages.
To examine the inhibitory mechanisms of hPH in
D‑GalN‑induced cytotoxicity, the HepG2 cells were assessed
by Annexin V and PI staining, followed by microplate analysis
(Fig. 3F and G) or fluorescence microscopy (Fig. 3H). D‑GalN
stimulation alone facilitated the induction of apoptosis, including
levels of Annexin V+ (841%)/PI+ (948%), compared with the

controls. By contrast, pretreatment with hPH significantly inhibited D‑GalN‑induced apoptosis (Annexin V+, 801%; PI+, 280%).
D‑GalN‑induced DNA fragmentation was also effectively
attenuated by hPH pretreatment (Fig. 3H). The present study
further examined whether hPH regulated PARP‑dependent
cell death. D‑GalN induced an increase of Bax (pro‑apoptotic
protein) and a decrease of Bcl‑2 (anti‑apoptotic protein) (Fig. 3I
and J). Furthermore, the cleavage of PARP was inhibited in the
HepG2 cells by pretreatment with hPH (Fig. 3I and J). These
findings suggested that hPH treatment significantly improved
hepatocyte degeneration through the attenuation of apoptosis in
HepG2 cells.
hPH regulates D‑GalN‑mediated intracellular ROS genera‑
tion and mitochondrial dysfunction. The rapid generation of
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Figure 2. Effects of hPH treatment on D‑GalN/LPS‑induced acute liver failure in tissue degeneration and apoptosis. (A) Histopathological staining. Upper
panel (magnification, x20), lower panel (magnification, x40). Scale bar=100 µm. The arrows indicate apoptotic hepatocytes (black), a severely affected region
of a lobule containing ballooned hepatocytes (red), and hepatocytes expanded by fat vacuoles (green). (B) Images showing PCNA staining. Scale bar=100 µm.
(C) Apoptotic response to D‑GalN/LPS in the liver tissue of rats was investigated using TUNEL staining. Scale bar=100 µm. (D) Stained sections were graded
for histopathology using a four‑point scale (0‑3), with 0, 1, 2, and 3 representing no damage, mild damage, moderate damage, and severe damage, respectively.
(E) PCNA‑positive cells were significantly less numerous in the D‑GalN/LPS‑treated group than in the control group; the addition of hPH led to significant
overexpression of PCNA in the liver compared with D‑GalN/LPS treatment alone. (F) TUNEL‑positive cells was higher in number in the group treated with
D‑GalN/LPS alone compared with the control group. However, apoptotic induction by D‑GalN/LPS was further reduced in the groups treated with 1.2, 2.4,
and 3.6 ml/kg of hPH. All data are presented as the mean ± standard error of the mean. *P<0.05 and **P<0.01, vs. D‑GalN/LPS group. hPH, human placental
hydrolysate; D‑GalN, D‑galactosamine; LPS, lipopolysaccharide; PCNA, proliferating cell nuclear antigen; Cont, control.

ROS is associated with hyperpolarization of the mitochondrial
membrane potential and apoptosis in D‑GalN‑treated hepatocytes (36). In addition, D‑GalN‑dependent cell necrosis is
associated with mitochondrial membrane depolarization (37).
To investigate whether the D‑GalN‑mediated increase in
abnormal mitochondria was rescued by hPH treatment, the
present study first evaluated mitochondrial morphology
using Tomm20 (mitochondrial outer membrane) staining
(Fig. 4A). Mitochondrial morphology was altered at 24 h in
the D‑GalN‑stimulated HepG2 cells. However, the increased
mitochondrial damage was attenuated significantly by hPH.
In addition, mitochondrial mass decreased, by ~55%, in the
D‑GalN‑stimulated HepG2 cells, and this was rescued by
hPH pretreatment (Fig. 4B). ΔΨm was then evaluated using
microplate analysis. The D‑GalN‑stimulated HepG2 cells

exhibited decreased ΔΨm; however, this decrease was significantly attenuated in the hPH‑pretreated cells and unstimulated
cells (Fig. 4C). These findings suggested that hPH improved
D‑GalN‑mediated mitochondrial dysfunction by improving
ΔΨm and inhibiting quantitative mitochondria loss.
Subsequently, the present study determined whether hPH
was involved in the negative regulation of oxidative stress.
The HepG2 cells were stimulated with D‑GalN in the presence or absence of hPH, and ROS generation was determined
using DCFH‑DA or MitoSOX (mitochondrial‑specific
superoxide indicator) (38) as a probe for microplate analyses
(Fig. 4D and E). D‑GalN alone led to the potent intracellular
generation of ROS, whereas the D‑GalN‑induced generation of ROS in HepG2 cells was attenuated significantly by
hPH pretreatment (Fig. 4D). Mitochondrial ROS increased
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Figure 3. Effects of hPH treatment on D‑GalN‑induced apoptosis in HepG2 cells. (A) HepG2 cells were treated with 25, 50, or 100 mM D‑GalN for 24 h.
Treatment with 50 mM D‑GalN yielded a cell viability of almost 50% compared with the vehicle control. The concentration of 50 mM D‑GalN was used to
determine the 50% inhibitory concentration. (B) HepG2 cells were treated with increasing concentrations of hPH or vehicle control for 24 h. HepG2 cells were
treated with hPH (5%) for 2 h prior to D‑GalN stimulation (50 mM). After 24 h, the hepatoprotective effects of hPH were assessed with the (C) Cell Counting
Kit‑8 assay and (D) LDH release test for cell viability, and with an (E) inverted phase‑contrast microscope for morphological changes (scale bar=50 µm).
HepG2 cells were stimulated with D‑GalN (50 mM, 24 h) in the presence or absence of 5% hPH. (F) Cells were subjected to fluorescence microscopy (PI stain
only) and (G) Annexin V/PI staining analyzed by a microplate (scale bar=50 µm). (H) DNA fragmentation (red arrow) and nuclear condensation (white
arrow) were detected by DAPI staining under each condition (scale bar=5 µm). For western blot analysis, cell lysates were collected and subjected to sodium
dodecyl sulfate‑PAGE, followed by immunoblot analysis using anti‑BCL2, anti‑BAX and anti‑PARP antibodies. Anti‑GAPDH was used as a loading control.
(I) Representative images and (J) densitometry. All data are presented as the mean ± standard error of the mean. **P<0.01, vs. D‑GalN group. hPH, human
placental hydrolysate; D‑GalN, D‑galactosamine; Cont, control; LDH, lactate dehydrogenase; BCL2, B‑cell lymphoma 2; BAX, Bcl‑2‑associated X protein;
PARP, poly (ADP) ribose polymerase; PI, propidium iodide.

significantly following treatment with D‑GalN (Fig. 4E),
whereas D‑GalN‑induced mitochondrial ROS generation

was decreased by pretreatment with hPH. These results
suggested that hPH protected against D‑GalN‑mediated
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Figure 4. D‑GalN‑induced mitochondrial dysfunction and ROS overgeneration in HepG2 cells are improved by hPH treatment. HepG2 cells were stimulated
with D‑GalN (50 mM, 24 h) in the presence or absence of 5% hPH. (A) HepG2 cells post‑hPH treatment were immunostained with anti‑Tomm20 antibody,
followed by the addition of Cy3‑conjugated secondary antibody. Nuclei were identified using DAPI staining (scale bar=5 µm). (B) MitoTracker fluorescence
signals for mitochondrial mass were measured. (C) ΔΨm was measured under the indicated conditions using the ΔΨm‑sensitive fluorochrome MitoTracker
Red CMXRos. (D) Cells were stained with 2',7'‑dichlorofluorescin diacetate for 30 min to measure intracellular hydrogen peroxide. (E) Cells were stained
with MitoSOX for 30 min to measure mitochondrial ROS. Bar graphs show relative analysis. All data are presented as the mean ± standard error of the mean.
**
P<0.01, vs. D‑GalN group. hPH, human placental hydrolysate; D‑GalN, D‑galactosamine; Con, control; MMP/ΔΨm, mitochondrial membrane potential;
ROS, reactive oxygen species.

apoptotic cell death by regulating the generation of cytosolic
and mitochondrial ROS.
hPH regulates expression of antioxidant enzymes in HepG2
cells. As the induction of antioxidant enzymes is a universal
stress response against liver degeneration and has been widely
shown to have an anti‑apoptotic effect, the expression levels
of antioxidative enzymes SOD1, SOD2, GPx, and catalase
were detected by western blot analysis (Fig. 5A). hPH induced
antioxidative enzyme expression in the HepG2 cells. These
enzymes were elevated 1 h following hPH treatment and were
maintained at this level until 8 h. Furthermore, to investigate
the antioxidant mechanisms of hPH, Nrf2 pathway‑related
gene expression on HepG2 cells was evaluated (Fig. 5B‑D). The
induction of Nrf2 upregulates antioxidant proteins, including
SOD, catalase, and HO‑1, reducing ROS (15). hPH treatment
resulted in a significant decrease of Keap1 at 4‑8 h. However,
hPH increased the protein levels of cytoplasmic p‑p62 and
HO‑1. Additionally, p62 was upregulated 4‑8 h following hpH
treatment (Fig. 5B). Furthermore, the expression of Nrf2 was
decreased in the cytosol and increased in the nucleus (active
Nrf2) following hPH treatment, indicating that translocation
to the nucleus was affected by hPH treatment (Fig. 5C and D).
Together, these findings indicated that the induction of antioxidative enzymes by hPH treatment was modulated by the
Keap1‑p62‑Nrf2 pathway.
hPH minimizes the expression of damage‑related molecules
via the regulation of autophagy. Autophagy, mitochondria, and oxidative stress are closely intertwined in redox
signalling (39). Additionally, D‑GalN‑induced cell damage
regulates the autophagy process in early stages. To investigate whether the regulation of autophagy is influenced

by D‑GalN stimulation and the effects of hPH, the present
study measured the level of autophagy regulation by staining
cells with anti‑LC3 I/II antibody (Fig. 6A). LC3 I/II is an
established autophagy marker due to its involvement in
autophagosome membrane formation (40). In the present
study, compared with the cells treated with vehicle control or
D‑GalN alone, the cells treated with hPH exhibited significantly fewer LC3 puncta per cell (Fig. 6A). The changes in
autophagy‑related genes were then quantified through assessment of RNA and protein levels in the hPH‑treated HepG2
cells. As shown in Fig. 6B and C, hPH treatment induced
a decrease in the conversion of LC3‑I to LC3‑II (lipidated
form), the latter of which is a reliable marker of autophagosome generation. Furthermore, the expression levels of
DRAM, CHOP, and p53 (proteins associated with autophagic
cell death) indicated that a minimized autophagy process
was induced in the hPH‑treated cells (Fig. 6B) (20,41,42).
Similarly, the transcription levels of autophagy‑related
genes (ATG8, CTSD, BECN1, and LAMP1) and of ER
stress‑related genes (ATF4, ATF6, and CHOP) were lower
in the hPH‑treated cells compared with those in cells treated
with D‑GalN only (Fig. 6C). These results suggested that
hPH treatment minimized the escalation of D‑GalN‑induced
autophagy processes in HepG2 cells.
Discussion
Apoptosis and oxidative stress are interrelated biological
events that are involved in the pathogenesis of various
diseases, including ALF (43‑46). Emerging evidence
suggests that D‑GalN/LPS‑induced oxidative stress gives
rise to hepatic injuries resulting from oxidative stress and
apoptosis, which parallel those of liver degeneration (6,7).
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Figure 5. Upregulation of antioxidant enzymes and regulation of Keap1‑Nrf2 in hPH‑treated HepG2 cells. (A) Lysates from hPH‑induced HepG2 cells were
immunoblotted with anti‑SOD‑1, anti‑SOD‑2, anti‑GPx, or anti‑catalase antibodies. Representative images (left penal), densitometry results (right panel). All
data are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01 vs. 0 h time point. (B) Following treatment with hPH, the expression levels
of p‑p62, p62, Keap1, and HO‑1 were determined by western blot analysis. Representative images (left penal), densitometry results (right panel). All data
are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, vs. 0 h time point. (C) Nuclear localization of Nrf2 in hPH‑treated HepG2 cells
compared with untreated HepG2 cells. Lysates from hPH‑treated HepG2 cells were immunoblotted with anti‑Nrf2, anti‑Lamin B1, or anti‑GAPDH antibodies.
Representative images (left penal), densitometry results (right panel). All data are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, vs. 0 h
time point. (D) HepG2 cells post‑hPH treatment were immunostained with anti‑Nrf2 antibody. Nuclei were identified using DAPI staining (scale bar=20 µm).
hPH, human placental hydrolysate; SOD, superoxide dismutase; GPx, glutathione peroxidase; Keap1, Kelch‑like ECH2‑associated protein 1; HO‑1, heme
oxygenase‑1; p‑p62; Nrf2, nuclear factor‑E2‑related factor 2.

In addition, D‑GalN/LPS‑induced ALF is widely accepted
as an experimental liver injury animal model, contributing
to investigation of the mechanisms underlying clinical liver
injury and the development of efficient hepatoprotective
materials (47‑51). Accordingly, any approach that relieves
apoptosis and oxidative stress in vitro and in vivo contributes
to the prevention or treatment of ALF. In the present study,
it was demonstrated that pretreatment with hPH attenuated
acute liver injury associated with elevated serum levels of
ALP, AST, LDH, and pro‑inflammatory cytokines (IL‑6
and TNF‑ α). Furthermore, it was found that apoptosis
was increased following D‑GalN/LPS injection, whereas
pretreatment with hPH effectively inhibited tissue degeneration and increased cell death in D‑GalN/LPS‑induced
acute liver injury. Pretreatment with hPH also reversed the
extensive vacuolization, severe intrahepatic hemorrhage,
destruction of nuclei, and loss of hepatic cords. Consistently,
it has been reported that hPH possesses a variety of biological activities, including anti‑inflammatory (26,52‑56) and
antioxidant (26,57‑59) properties. Exposure to hazardous
components from the environment can lead to pregnancy
loss, uterine dysfunction, or fetal death (60). It has been
reported that oxidative stress is mainly or partly involved in
damage from these harmful environments (61). Therefore,
the human placenta contains antioxidant defense substances
to protect embryos from oxidative stress (62‑64). Human
placenta extract prepared from the placenta of healthy pregnant females is known to have various physiological actions,

including antioxidative properties (57,65). In the present study,
hPH was prepared with human placenta, including umbilical
cord, following the provision of consent from the pregnant
women. The hydrolysate of human placenta is manufactured
by a chemical process with HCl and pepsin, followed by
dialysis, heat treatment and hydrolysis. This hydrolysate
contains various amino acids, including arginine (0.08%),
lysine (0.1%), phenylalanine (0.08%), tyrosine (0.03%),
leucine (0.12%), methionine (0.03%), valine (0.04%), alanine
(0.08%), serine (0.07%), and threonine (0.06%). Based on
this, hPH is considered to contain the cleaved proteins of the
amino acids and their active ingredients.
In previous studies, it has been reported that D‑GalN
leads to cytotoxicity and apoptotic cell death in HepG2
cells (66‑68). D‑GalN/LPS intoxication causes an imbalance between pro‑oxidants and antioxidants, involving the
excessive production of ROS and a deficiency of cellular antioxidants, including glutathione, catalase and SOD. Oxidative
stress caused by D‑GalN/LPS is a recognized phenomenon
in liver damage (47,69‑71). In addition, D‑GalN/LPS induces
loss of ΔΨm and production of ROS, resulting in liver
damage (36,72‑74). Mitochondria are the major subcellular
organelles responsible for ROS production (75). The results
of the present study demonstrated that hPH enhanced the
expression of SOD‑1, SOD‑2, catalase and GPx, and increased
the nuclear translocation of the Nrf2 via a Keap1‑p62‑Nrf2
mechanism. The upregulation of various important antioxidants is caused by the binding of Nrf2 to the ARE of
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Figure 6. hPH treatment results in altered autophagy regulation in HepG2 cells following D‑GalN stimulation. (A) HepG2 cells treated with hPH exhibit
minimized autophagy flux. To detect autophagosomes, cells were immunostained with anti‑LC3 antibody. Nuclei were identified using DAPI staining (scale
bar=10 µm). (B) Cell lysates were immunoblotted with anti‑LC3 I/II, anti‑DRAM, anti‑CHOP, anti‑p53, or anti‑GAPDH antibodies. Representative western
blot images (left panel) and densitometry results (right panel). All data are presented as the mean ± standard error of the mean. **P<0.01, vs. D‑GalN group.
(C) Transcript levels of ER stress‑ and autophagy‑related genes were determined by reverse transcription‑quantitative polymerase chain reaction analysis. All
data are presented as the mean ± standard error of the mean. **P<0.01, vs. D‑GalN group. hPH, human placental hydrolysate; D‑GalN, D‑galactosamine; Cont,
control; LC3, microtubule‑associated protein 1A/1B‑light chain 3; DRAM, damage‑regulated autophagy modulator; CHOP, C/EBP homologous protein; ATF,
activating transcription factor; BECN1; beclin 1; LAMP1, lysosomal‑associated membrane protein 1.

antioxidant target proteins, including SOD, catalase, NQO1,
GCLM and HO‑1 (15,16). Nrf2 has been regarded as a novel
therapeutic target for the treatment of liver disease (76‑80).
In Nrf2‑deficient mice, the expression of various cytoprotective enzymes was decreased in hepatocytes, resulting in
oxidative stress and markedly delayed liver regeneration (81).
In addition, genetic disruption of Nrf2 triggers the progression of necroinflammation and hepatic fibrosis in Hfe‑/‑ mice
presenting with no liver injury (82). Pretreatment with
sulforaphane prevents hepatic damage induced by intestinal
ischemia/reperfusion in rats through an antioxidative effect
via the Nrf2‑ARE pathway (79). Another study showed that
the expression of Nrf2 was upregulated to protect the liver

from inflammatory damage caused by oxidative stress during
the development of non‑alcoholic fatty liver and steatohepatitis (78). Additionally, Farombi et al reported that curcumin
(diferuloymethane) administration promoted the nuclear
translocation and ARE‑binding of Nrf2, leading to prevention of dimethylnitrosamine‑induced hepatotoxicity (76). In
addition, β ‑cryptoxanthin was found to ameliorate visceral
fat and cardiometabolic health risk factors by modulating the
expression of nuclear factor‑κ B and Nrf2 in rats fed a high‑fat
diet (83).
Autophagy is an evolutionarily conserved homeostatic
process and lysosome‑dependent proteolytic pathway, which
is involved in a variety of physiological and pathological
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processes (84,85). According to previous data, autophagy
is involved in major liver diseases, including liver ischemia/reperfusion injury, hepatitis B and C, hepatocellular
carcinoma, alcoholic liver disease and non‑alcoholic fatty
liver disease (86). In addition, autophagy is induced to maintain healthy cells in the presence of TNF‑, acetaminophen‑,
or ethanol‑induced liver injury (87‑89). However, excessive
autophagy can cause autophagic cell death. Previously,
autophagy has been shown to be elevated in concanavalin
A‑induced acute hepatitis, leading to the autophagic
cell death of hepatoma cells in SCID/NOD mice (90).
Furthermore, autophagy inhibition significantly improved
liver graft dysfunction and the survival rate of recipient rats
with ‘cold ischemia‑warm reperfusion injury’ associated
with liver transplantation (91), suggesting that autophagy can
aggravate liver damage. In the present study, it was found
that excessive autophagy was induced following D‑GalN
administration, and that pretreatment with hPH effectively
suppressed this enhanced autophagy in D‑GalN‑induced
HepG2 cells. It also indicated a regulatory pathway mechanism of autophagy induction and inhibition by D‑GalN/hPH
via the p53‑DRAM‑autophagy axis. The identification of
DRAM as a p53 target mediating the induction of autophagy
allowed for investigation of the role of autophagy in apoptosis (42). Liu et al reported that p53‑induced apoptosis
is primarily dependent on DRAM‑ and BAX‑mediated
autophagy in hepatosteatosis in oleic acid‑treated HepG2
cells and high‑fat diet mice (92). The induction of autophagy
by the nuclear translocation of p53 involves the upregulation of DRAM and sestrin2 in p53‑sufficient, but not in
p53‑deficient cells (93). The expression of CHOP is regulated
transcriptionally and post‑transcriptionally in hPH‑induced
HepG2 cells. CHOP, a multifunctional transcription factor
in the ER stress response, promotes autophagic apoptosis
induced by various stimuli, including tetrahydrocannabinol,
2‑deoxy‑D‑glucose, rabbit hemorrhagic disease virus, and
apoptosis‑stimulating protein of p53‑2 (94‑97). The data
obtained in the present study also demonstrated that hPH
led to downregulation of the ER stress‑related downstream
targets, ATF4 and ATF6, in D‑GalN‑treated HepG2 cells.
Based on the above findings, it was concluded that autophagy,
apoptosis and ER stress are closely associated with each
other, supported by the results of the present study. D‑GalN
stimulation increased the expression levels of DRAM,
CHOP and the apoptosis‑related protein p53 in HepG2 cells,
whereas hPH pretreatment reversed the expression of these
proteins. hPH pretreatment also resulted in LC3 lipidation,
but meaningfully minimized autophagosome expression
compared with D‑GalN alone.
In previous animal studies, early onset autophagy has been
shown to increase liver injury, however, this observation has
not been corroborated in patient populations. Therefore, the
epidemiological relevance of autophagy and liver damage
require investigation in the future. Taken together, the results
of the present study showed that hPH had a protective effect
on hepatocyte apoptosis through antioxidative modulation and minimization of the autophagy process, which
resulted in the inhibition of hepatocytotoxicity. This may be
useful as a target for the treatment of acute liver injury. The
identification of this pathway can assist in understanding

the molecular events leading to the activation of oxidative
stress‑ and autophagy‑mediated cell death in human disease,
and contribute to the design of novel therapeutic strategies
for inhibiting liver disease and preventing fulminant hepatic
failure.
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